Vulnerable Plaque Natural History Key To Device Trial, Swift Approvals
This article was originally published in The Gray Sheet
Executive Summary
Clinical trials supporting devices and diagnostics for vulnerable plaques (VP) should include analysis of the natural history of the vascular disease, according to FDA Office of Device Evaluation's Donald Jensen
You may also be interested in...
Optical Imaging Indicates Multifocal Approach To Coronary Lesion Treatment
Systematic treatment of coronary inflammation should accompany localized treatment of vulnerable plaques in prevention strategies for myocardial infarction, according to an analysis by Massachusetts General Hospital's Wellman Center for Photomedicine
Guidant Awaits SPIRIT Trial Data For Clear Vision Of Future Stent Business
Feasibility data on the Multi-Link Vision cobalt-chromium, durable-polymer, everolimus-eluting stent will be key to predicting the stability of Guidant's DES technology platform in the post-Dollens era
Thoratec Makes Case For Permanent VAD Higher Medicare Reimbursement
Thoratec is expecting CMS to boost Medicare reimbursement for mechanical cardiac assist device implantation based on data showing that the firm's HeartMate XVE left ventricular assist device (LVAD) is a cost-effective destination therapy for end-stage heart failure patients